Is Rainbow Rare Earths Mispriced Ahead of Its Feasibility Study

A company that Benchmark Mineral Intelligence rates alongside China’s Bayan Obo as one of the lowest-cost rare earth producers in the Western world is trading at a market capitalisation of roughly US$215-225 million. Its projected attributable EBITDA across two projects is estimated to reach US$300 million annually by 2030.

That arithmetic sits at the centre of the Rainbow Rare Earths investment case, and it arrives at a moment when Western governments have moved from rhetoric to signed contracts. NdPr price floors, US International Development Finance Corporation equity commitments, and Pentagon supply agreements have reshaped the risk-return calculus for pre-production rare earth developers. Rainbow sits inside that policy framework at a specific inflection point: a definitive feasibility study currently 75% complete and a final investment decision targeted for Q3 2027.

The question worth answering is whether the current valuation reflects or misprices the project quality, the policy backstops, and the execution risks still ahead. Here is a structured read on where Rainbow sits in the risk-to-return spectrum relative to peers. Not a buy or sell call, but the framework to form your own.

Two projects, one differentiated model: what Rainbow is actually building

Before the economics land, one structural fact needs to sit clearly in place: Rainbow does not mine rare earths in the conventional sense. It extracts them from phosphogypsum, a byproduct left over from phosphoric acid production.

That distinction removes an entire category of cost and risk. There is no open pit to construct, no village to relocate, no new road network to build, and no grid connection to fund. The feedstock already exists as waste, which is why Benchmark Mineral Intelligence places Rainbow among the lowest-cost producers outside China, and why Augustea Media independently ranks it as the second-highest margin rare earth operation globally.

The phosphogypsum extraction model sits outside the cost structure of almost every hard-rock developer precisely because the feedstock already exists as an industrial byproduct, removing the capital and environmental burden of creating a new mine footprint from scratch.

For an investor comparing Rainbow against other Western developers, this is the point that changes everything downstream. The capital requirement, the permitting pathway, and the operational risk profile are structurally different from almost every hard-rock peer.

Phalaborwa: processing 60 years of legacy stacks

Phalaborwa in South Africa is the more advanced asset, roughly 75% through its definitive feasibility study. It targets 35 million tonnes of finite phosphogypsum stacks accumulated over 60 years of chemical processing.

At a throughput of 2.2Mt per year and around 65% recovery, the facility is designed to yield approximately 1,850 tonnes per year of high-purity NdPr oxide, plus a mixed rare earth carbonate containing roughly 80 tonnes per year of dysprosium and terbium. Mine life is 16 years, with capital expenditure estimated at US$325-350 million. Rainbow owns 85% and targets a final investment decision in Q3 2027.

Uberaba: a live feed with a 30-year runway

Uberaba in Brazil operates on different logic. Rather than processing finite legacy stacks, it takes fresh feed directly from Mosaic’s ongoing phosphoric acid production, giving it a projected life exceeding 30 years.

The formal pre-feasibility study commenced on 7 September 2026, with a DFS targeted for 2028 and initial production around the end of 2030. Capital expenditure is estimated at US$279-280 million, and on a positive DFS the joint venture will be fixed at 51% Mosaic and 49% Rainbow.

The economics behind the valuation gap

The margin figures are what make the valuation gap worth examining, and Phalaborwa carries the clearest numbers. A December 2024 study using a US$110/kg NdPr spot price projected average annual revenue of approximately US$250 million, EBITDA of around US$180 million, an EBITDA margin of 70-75%, and a post-tax internal rate of return of 38-45%. At the updated pricing management has since presented, estimated annual EBITDA rises to US$210-220 million.

Uberaba’s economics, drawn from a March 2026 preliminary assessment, look stronger again. At March 2026 spot pricing, the post-tax NPV₁₀ is estimated at US$916 million, the IRR exceeds 45%, and the EBITDA margin sits above 70%. Average annual EBITDA is estimated at US$217 million, of which Rainbow’s 49% share equates to roughly US$106-110 million.

Combine the two and attributable EBITDA reaches an estimated US$300 million annually by 2030. That is the figure the current market capitalisation has to be weighed against.

Where NdPr pricing actually sits

The credibility of those margins depends entirely on the NdPr price assumption underpinning them, and the picture here is not settled. Three reference points frame it:

• SMM spot benchmark: US$96.69/kg as of 5 September 2026
• Western government floor price: US$110/kg via contract-for-difference agreements
• Adamas Intelligence long-run incentive price: approximately US$150/kg

The gap between the US$110/kg floor and a spot price below US$97/kg is the live issue for any developer that has not yet signed an offtake or a government contract. Western floor prices exist through named deals with MP Materials and Lynas; they are not universally available. A developer exposed to spot alone is exposed to the lower number.

The heavy rare earth divergence hiding in the numbers

The most underappreciated element of Rainbow’s economics is not NdPr at all. It is the pricing bifurcation in dysprosium and terbium, the heavy rare earths Phalaborwa also produces.

Chinese domestic spot dysprosium trades at roughly US$205-220/kg, against ex-China indicative pricing of US$1,100-2,000+/kg. For terbium, Chinese spot sits near US$995-1,005/kg, against ex-China indicative levels of US$2,050-5,000+/kg. US government floor prices have been set at US$575/kg for dysprosium and US$2,050/kg for terbium.

The implication for the investor is worth pausing on. If ex-China pricing for these heavy rare earths holds anywhere near published indicative levels, Rainbow’s headline EBITDA projections, built largely on NdPr, are conservative rather than optimistic. That is a rare direction for a pre-production developer’s numbers to lean, and it is a reason to stress-test the figures upward, not only down.

The ex-China heavy rare earth premium is not simply a temporary arbitrage; the structural reasons it persists, including processing concentration, export licensing, and limited qualifying substitute supply, are why the published indicative levels for dysprosium and terbium outside China sit at multiples of domestic Chinese spot rather than modest premiums.

How the market is valuing Rainbow and what peer transactions imply

At an LSE market capitalisation of roughly £165-170 million (US$215-225 million) as of September 2026, Rainbow trades at a small fraction of its projected 2030 attributable EBITDA of US$300 million. On its face, that implies a striking discount. The analytical work is in establishing what would have to be true for that discount to be rational versus a genuine mispricing.

Recent peer transactions provide one reference frame. In April 2026, USA Rare Earth agreed to acquire the Serra Verde rare earth project in Brazil for approximately US$2.8 billion. Separately, the US Department of Defense took a 15% stake in MP Materials through a US$400 million convertible preferred equity investment, while Lynas secured a US$96 million Pentagon supply agreement.

The Western rare earth supply chain vulnerabilities that created the policy environment Rainbow operates in, including concentrated Chinese processing capacity, limited ex-China separation infrastructure, and the absence of price discovery mechanisms outside China, are why government floor prices and DFI equity commitments exist as instruments at all.

Why London listings trade at a discount

These benchmarks do not automatically make Rainbow undervalued, because where a company lists matters. Edison Investment Research notes that London-listed mining equities typically trade at a 20-42% discount to North American peers.

The drivers are structural: exclusion from major indices, a retail-heavy investor base, lower liquidity, and greater distance from the US defence procurement relationships now driving sovereignty premia. Rainbow has engaged BMO to evaluate a potential US listing, which frames that discount as something management is actively trying to close.

One data point captures the dynamic starkly. When the Uberaba joint venture was announced in March 2026, Mosaic’s market capitalisation rose by over US$1 billion, while Rainbow’s rose by approximately US$30 million on the same deal.

The market assigned more than thirty times the value of Rainbow’s gain to Mosaic’s participation. That is either rational risk-weighting of a pre-production developer against an established fertiliser giant, or a structural pricing anomaly of the kind a US listing might begin to correct. Which reading you take shapes the entire investment thesis.

What de-risks the case and what still has to go right

The asymmetry worth understanding is between what has already been de-risked and what remains fully open. Genuine validation has arrived. Critical minerals fund TechMet holds an approximate 12% stake, and through TechMet the US International Development Finance Corporation has committed US$50 million in project equity for Phalaborwa, converting at final investment decision.

The DFC’s US$50 million commitment reduces Rainbow’s remaining equity requirement for Phalaborwa to approximately US$70 million. It is the single most quantitatively significant de-risking event to date, but it covers equity only. Debt financing still has to be secured separately.

That distinction defines the open risks. Rainbow intends to debt-finance roughly two-thirds of project costs, implying around US$210 million for Phalaborwa and about US$182 million for Uberaba. The four risks that remain live sit here:

• Technology scale-up: Phalaborwa is the first commercial recovery of rare earths from phosphogypsum at this scale, and the hydrometallurgical circuit remains unproven in full production.
• Financing execution: Raising equity before bankability at current market valuations carries dilution risk that analysts have flagged explicitly.
• Policy reversibility: Western price floors are deal-specific and politically contingent, and analysts warn China could keep spot prices low to undermine spot-exposed Western developers.
• Permitting and environmental: Phosphogypsum radioactivity is lower than hard-rock deposits, but water use, rehabilitation, and Phalaborwa’s proximity to Kruger National Park invite rigorous scrutiny.

For the investor, the DFC commitment is validating but not comprehensive. The critical open question is not whether Rainbow can reach a final investment decision, but whether it can reach bankability and close debt financing on terms that preserve equity value.

That question will not be answered until the DFS is complete. Treating the case as either uniformly de-risked or uniformly speculative misreads where the real uncertainty sits.

This article is for informational purposes only and should not be considered financial advice. Investors should conduct their own research and consult with financial professionals before making investment decisions. Past performance does not guarantee future results. Financial projections are subject to market conditions and various risk factors, and forward-looking statements are speculative and subject to change based on market developments and company performance.

Where the investment case stands ahead of the DFS and what to watch

The economics, the pricing context, the valuation gap, and the risk register all converge on a single event. The DFS is not merely a technical document; it is what converts the current probabilistic case into a bankable project with fixed economics, and its figures will either validate or force a material reassessment of the framework laid out above.

Three variables will move the case most over the next 12-18 months, ranked by analytical priority:

1. DFS completion, and the capex and IRR figures it confirms for Phalaborwa.
2. Debt financing progress, given that roughly two-thirds of project costs depend on it and dilution risk sits on the equity side.
3. NdPr spot price trajectory relative to the US$110/kg floor, with SMM spot at US$96.69/kg as of 5 September 2026 defining the live spread.

Alongside these, the BMO-led evaluation of a US listing is worth monitoring as a separate catalyst, given the 20-42% structural discount London-listed peers carry.

The timeline gives the sequence to track: Phalaborwa DFS completion, FID in Q3 2027, and initial production in H1 2029, with Uberaba’s PFS in 2027, DFS in 2028, and first production around the end of 2030. Each milestone is a point at which the valuation framework can be tested against fresh figures rather than projections.

For investors wanting to test the EBITDA-to-market-cap framework against a broader set of pre-production developers, our full explainer on rare earth developer valuation examines how the gap between projected economics and realised market capitalisation typically closes, or fails to close, across the mine-to-magnet value chain.